Vaccines

20 Apr 2018 Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives
19 Apr 2018 NovaDigm Therapeutics Announces Initiation of Phase 2a Clinical Trial of NDV-3A in Staphylococcus aureus
19 Apr 2018 Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease
18 Apr 2018 Elios Therapeutics Presents Initial Phase 2b Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the American Association for Cancer Research (AACR) 2018 Annual Meeting
17 Apr 2018 Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine
16 Apr 2018 Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors
15 Apr 2018 Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
15 Apr 2018 Personalized tumor vaccine shows promise in pilot trial
12 Apr 2018 Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
05 Apr 2018 Vivaldi Biosciences Presents Data at the World Vaccine Congress Demonstrating Potential of deltaFLU as Universal Influenza Vaccine
02 Apr 2018 SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1+/2+ Breast Cancer Patients
28 Mar 2018 Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
27 Mar 2018 Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection
20 Mar 2018 AJ Vaccines successfully completes two phase III trials of its new low-dose IPV-Al vaccine
19 Mar 2018 SELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting
19 Mar 2018 Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
16 Mar 2018 OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
16 Mar 2018 TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research
14 Mar 2018 Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
14 Mar 2018 Phase 1 clinical trial for Hantavirus vaccines yields positive interim results
13 Mar 2018 Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya
13 Mar 2018 Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program
08 Mar 2018 Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
08 Mar 2018 VBL Therapeutics Announces Top-Line Results from Pivotal Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma
05 Mar 2018 Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top